Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. This approach ensures product integrity throughout the supply chain.

Nintedanib is used to target fibrotic lung disease pathways and certain oncologic indications.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces the rate of forced vital capacity decline. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and stabilises fibrotic changes. - Non‑small cell lung cancer: used in combination regimens to inhibit tumour growth and angiogenesis, contributing to disease control.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness that may reduce appetite. - Vomiting: occasional episodes, usually self‑limiting. - Abdominal pain: discomfort in the stomach area. - Decreased appetite: reduced desire to eat, potentially leading to weight loss.

Serious or Rare Side Effects: - Elevated liver enzymes: indicates potential hepatic injury and requires monitoring. - Bleeding events: increased risk of gastrointestinal or other hemorrhage. - Cardiovascular events: such as myocardial infarction or stroke. - Gastrointestinal perforation: rare but serious intestinal injury.

When prescribing Nintedanib, clinicians should observe several safety considerations to minimise risk.

- Liver function monitoring: assess baseline enzymes and repeat regularly during therapy. - Bleeding risk assessment: evaluate concomitant anticoagulant use and history of haemorrhage. - Cardiovascular evaluation: screen for recent myocardial infarction or uncontrolled hypertension. - Pregnancy and lactation: avoid use as safety data are insufficient; discontinue if pregnancy occurs. - Drug interactions: review concomitant medicines that affect CYP3A4 or P‑gp pathways. - Renal function: monitor in patients with severe impairment. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Nintedanib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and toxicity. - Potent P‑glycoprotein inhibitors (e.g., verapamil): can raise plasma concentrations. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): may exacerbate haemorrhagic events.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly increase levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antacids or proton‑pump inhibitors: could affect absorption, monitor therapeutic response. - Diuretics: may increase risk of dehydration, monitor electrolytes.